The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Open accessAbstract
After 20 years follow‐up of newly diagnosed patients with Parkinson's disease (PD), 100 of 136 (74%) have died. The mortality rate fell in the first 3 years of treatment, then rose compared to the general population, the standardized mortality ratio from 15 to 20 years reaching 3.1. Drug induced dyskinesia and end of dose failure were experienced by most patients, but the main current problems relate to the non‐levodopa responsive features of the disease. Dementia is present in 83% of 20‐year survivors. Dementia correlates with increasing age and probably reflects an interplay of multiple pathologies. Seventeen people with dementia had postmortems. Eight had diffuse Lewy bodies as the only cause of dementia, while others had mixed neuropathology. Only one person lives independently and 48% are in nursing homes. Excessive daytime sleepiness is noted in 70%, falls have occurred in 87%, freezing in 81%, fractures in 35%, symptomatic postural hypotension in 48%, urinary incontinence in 71%, moderate dysarthria in 81%, choking in 48%, and hallucinations in 74%. The challenge is to understand the cellular mechanisms underlying the diverse features of advanced PD that go far beyond a lack of dopamine. © 2008 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025 · cited 1×
“Depression was assessed by the 30 item Geriatric Depression Scale (GDS).(23) Hallucinations were detected by routine questioning at each visit of the patient, and carer when present.”
MethodThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationA New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
The FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., Zaccai, J., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,689
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study
Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,401
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Self-citation
Research works printed but not linked: 4
- Kaplan E, 1983, The Boston naming test
- StataCorp 2005 Stata Statistical Software: Release 9
- 10.1212/WNL.40.1.38 · DOI
- 10.1007/s00415-006-0234-8 · DOI · Paper page
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationDiagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Self-citationClinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
The MoCA: Well-suited screen for cognitive impairment in Parkinson disease
Dalrymple-Alford, J. C., MacAskill, M. R., Nakas, C. T., Livingston, L., Graham, C., Crucian, G. P., Melzer, T. R., Kirwan, J., Keenan, R., Wells, S., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fc29c9 · Cited by 932
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3549 · Cited by 869
Parkinson's Disease and Parkinsonism: Neuropathology
Dickson, D. W. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009258 · Cited by 847
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“Of PD patients, 80% will develop dementia if they survive for 20 years with their illness, and this complication can be more disabling than their locomotor problems.(120) Dementia may arise as a consequence of cortical Lewy-body disease, coexistent Alzheimer or small vessel pathology, and the degeneration of monoamine…”
Self-citationMDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
Litvan, I., Aarsland, D., Adler, C. H., Goldman, J. G., Kulisevsky, J., Mollenhauer, B., Rodriguez‐Oroz, M. C., Tröster, A. I., & Weintraub, D. (2011) · Movement Disorders · doi:10.1002/mds.23823 · Cited by 805
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Self-citationThe CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Williams-Gray, C. H., Mason, S. L., Evans, J. R., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 681
Non-motor symptoms in Parkinson's disease
Pfeiffer, R. F. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.004 · Cited by 644
Circuit Mechanisms of Parkinson’s Disease
McGregor, M. M., & Nelson, A. B. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.004 · Cited by 624
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
The epidemiology of dementia associated with Parkinson disease
Aarsland, D., & Kurz, M. W. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.034 · Cited by 578
Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment
Pagonabarraga, J., Kulisevsky, J., Strafella, A. P., & Krack, P. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00019-8 · Cited by 549
Long-term effects of exercise and physical therapy in people with Parkinson disease
Mak, M. K., Wong-Yu, I. S., Shen, X., & Chung, C. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.128 · Cited by 549
Recurrent Falls in Parkinson’s Disease: A Systematic Review
Allen, N. E., Schwarzel, A. K., & Canning, C. G. (2013) · Parkinson's Disease · doi:10.1155/2013/906274 · Cited by 539
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson, P., Westman, E., Ballard, C., & Aarsland, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70152-7 · Cited by 499
Visual dysfunction in Parkinson’s disease
Weil, R. S., Schrag, A. E., Warren, J. D., Crutch, S. J., Lees, A. J., & Morris, H. R. (2016) · Brain · doi:10.1093/brain/aww175 · Cited by 481
“Visual hallucinations are also common in Parkinson’s disease, with a reported prevalence as high as 74% after 20 years of disease (Fenelon et al., 2000; Hely et al., 2008).”
BackgroundExecutive dysfunction in Parkinson's disease: A review
Dirnberger, G., & Jahanshahi, M. (2013) · Journal of Neuropsychology · doi:10.1111/jnp.12028 · Cited by 486
Advances in the genetics of Parkinson disease
Trinh, J., & Farrer, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.132 · Cited by 466
A clinico-pathological study of subtypes in Parkinson's disease
Selikhova, M., Williams, D. R., Kempster, P. A., Holton, J. L., Revesz, T., & Lees, A. J. (2009) · Brain · doi:10.1093/brain/awp234 · Cited by 461
Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease: A Blinded Evaluation
Castrioto, A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.182 · Cited by 455
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Epidemiology of Parkinson's disease
Elbaz, A., Carcaillon, L., Kab, S., & Moisan, F. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.09.012 · Cited by 445
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Parkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study
Yarnall, A. J., Breen, D. P., Duncan, G. W., Khoo, T. K., Coleman, S. Y., Firbank, M. J., Nombela, C., Winder-Rhodes, S., Evans, J. R., Rowe, J. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000066 · Cited by 422
Genetics and Pathogenesis of Parkinson's Syndrome
Ye, H., Robak, L. A., Yu, M., Cykowski, M., & Shulman, J. M. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-034145 · Cited by 416
The progression of pathology in longitudinally followed patients with Parkinson’s disease
Halliday, G., Hely, M., Reid, W., & Morris, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0344-8 · Cited by 414
Self-citationClinical and physiological assessments for elucidating falls risk in Parkinson's disease
Latt, M. D., Lord, S. R., Morris, J. G. L., & Fung, V. S. C. (2009) · Movement Disorders · doi:10.1002/mds.22561 · Cited by 402
Self-citationKelly, V. E., Eusterbrock, A. J., & Shumway-Cook, A. (2012) · Parkinson's Disease · doi:10.1155/2012/918719 · Cited by 398
Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology
Del Tredici, K., & Braak, H. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12298 · Cited by 398
Exploring Braak’s hypothesis of Parkinson’s disease
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A., & Kraneveld, A. D. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00037 · Cited by 395
A 12-Year Population-Based Study of Psychosis in Parkinson Disease
Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Goetz, C. G., Stebbins, G. T., Aarsland, D., & Alves, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.166 · Cited by 394
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
Parkinson’s disease: The non-motor issues
Chaudhuri, K. R., Odin, P., Antonini, A., & Martinez-Martin, P. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.02.018 · Cited by 388
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 385
APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies
Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.600 · Cited by 378
Leroi, I., McDonald, K., Pantula, H., & Harbishettar, V. (2012) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988712464823 · Cited by 378
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
The neurobiological basis of cognitive impairment in Parkinson's disease
Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H. (2014) · Movement Disorders · doi:10.1002/mds.25857 · Cited by 366
Self-citationEpidemiology of Parkinson Disease
Lee, A., & Gilbert, R. M. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.012 · Cited by 366
McCann, H., Stevens, C. H., Cartwright, H., & Halliday, G. M. (2014) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70017-8 · Cited by 364
Self-citationEye movements in patients with neurodegenerative disorders
Anderson, T. J., & MacAskill, M. R. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.273 · Cited by 363
New horizons in multimorbidity in older adults
Yarnall, A. J., Sayer, A. A., Clegg, A., Rockwood, K., Parker, S., & Hindle, J. V. (2017) · Age and Ageing · doi:10.1093/ageing/afx150 · Cited by 361
Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale
Martínez-Martín, P., Rodríguez-Blázquez, C., Alvarez, M., Arakaki, T., Arillo, V. C., Chaná, P., Fernández, W., Garretto, N., Martínez-Castrillo, J. C., Rodríguez-Violante, M., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.10.026 · Cited by 360
The role of the medial prefrontal cortex in cognition, ageing and dementia
Jobson, D. D., Hase, Y., Clarkson, A. N., & Kalaria, R. N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab125 · Cited by 338
New evidence on the management of Lewy body dementia
Taylor, J.-P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., Allan, L. M., Thomas, A. J., & O'Brien, J. T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30153-x · Cited by 347
Neuropathology and molecular diagnosis of Synucleinopathies
Koga, S., Sekiya, H., Kondru, N., Ross, O. A., & Dickson, D. W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00501-z · Cited by 347
The Epidemiology of Dementia Associated with Parkinson's Disease
Aarsland, D., & Kurz, M. W. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00369.x · Cited by 338
Mood and behavioural effects of subthalamic stimulation in Parkinson's disease
Castrioto, A., Lhommée, E., Moro, E., & Krack, P. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70294-1 · Cited by 333
Epidemiology of psychosis in Parkinson's disease
Fénelon, G., & Alves, G. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.014 · Cited by 330
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease
Gagnon, J., Vendette, M., Postuma, R. B., Desjardins, C., Massicotte‐Marquez, J., Panisset, M., & Montplaisir, J. (2009) · Annals of Neurology · doi:10.1002/ana.21680 · Cited by 325
Hallucinations in Parkinson disease
Diederich, N. J., Fénelon, G., Stebbins, G., & Goetz, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.62 · Cited by 312
Prognosis of Mild Cognitive Impairment in Early Parkinson Disease: The Norwegian ParkWest Study
Pedersen, K. F., Larsen, J. P., Tysnes, O.-B., & Alves, G. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2110 · Cited by 315
EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia
Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H., Nacmias, B., Pasquier, F., Popescu, B. O., Rektorova, I., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03784.x · Cited by 306
Adult Neurogenesis in Neurodegenerative Diseases: Figure 1.
Winner, B., & Winkler, J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021287 · Cited by 305
What predicts mortality in Parkinson disease?: A prospective population-based long-term study
Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., & Alves, G. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f61311 · Cited by 302
Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease: Two Case Reports
Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., Jahanshahi, M., Widner, H., Rehncrona, S., Brundin, P., Björklund, A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4749 · Cited by 300
Del Tredici, K., Hawkes, C. H., Ghebremedhin, E., & Braak, H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0665-2 · Cited by 295
Baba, T., Kikuchi, A., Hirayama, K., Nishio, Y., Hosokai, Y., Kanno, S., Hasegawa, T., Sugeno, N., Konno, M., Suzuki, K., et al. (2012) · Brain · doi:10.1093/brain/awr321 · Cited by 284
Effects of Exercise on Falls, Balance, and Gait Ability in Parkinson’s Disease: A Meta-analysis
Shen, X., Wong-Yu, I. S. K., & Mak, M. K. Y. (2016) · Neurorehabilitation and Neural Repair · doi:10.1177/1545968315613447 · Cited by 277
Gait disorders and balance disturbances in Parkinsonʼs disease: clinical update and pathophysiology
Boonstra, T. A., van der Kooij, H., Munneke, M., & Bloem, B. R. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328305bdaf · Cited by 274
Clinical spectrum of levodopa‐induced complications
Aquino, C. C., & Fox, S. H. (2015) · Movement Disorders · doi:10.1002/mds.26125 · Cited by 270
Course in Parkinson disease subtypes: A 39-year clinicopathologic study
Rajput, A. H., Voll, A., Rajput, M. L., Robinson, C. A., & Rajput, A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ae7af1 · Cited by 270
Network connectivity determines cortical thinning in early Parkinson’s disease progression
Yau, Y., Zeighami, Y., Baker, T. E., Larcher, K., Vainik, U., Dadar, M., Fonov, V. S., Hagmann, P., Griffa, A., Mišić, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02416-0 · Cited by 270
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Neuropathology of non-motor features of Parkinson disease
Dickson, D. W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K. A., Frigerio, R., Burnett, M., Parisi, J. E., Klos, K. J., & Ahlskog, J. E. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70769-2 · Cited by 266
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study
Alcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M.-X., Rosado, L., Orbe Reilly, M., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d54b · Cited by 262
Cognitive impairment and dementia in Parkinson's disease
Pagonabarraga, J., & Kulisevsky, J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.029 · Cited by 257
Longitudinal study of normal cognition in Parkinson disease
Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002001 · Cited by 251
The relationship between quality of life and swallowing in Parkinson's disease
Plowman‐Prine, E. K., Sapienza, C. M., Okun, M. S., Pollock, S. L., Jacobson, C., Wu, S. S., & Rosenbek, J. C. (2009) · Movement Disorders · doi:10.1002/mds.22617 · Cited by 233
Bras, J., Guerreiro, R., Darwent, L., Parkkinen, L., Ansorge, O., Escott-Price, V., Hernandez, D. G., Nalls, M. A., Clark, L. N., Honig, L. S., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu334 · Cited by 230
Self-citationCerebrospinal fluid biomarkers in Parkinson disease
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209
Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
Petrou, M., Dwamena, B. A., Foerster, B. R., MacEachern, M. P., Bohnen, N. I., Müller, M. L., Albin, R. L., & Frey, K. A. (2015) · Movement Disorders · doi:10.1002/mds.26191 · Cited by 208
Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia
Y.Y. Szeto, J., & J.G. Lewis, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208112754 · Cited by 198
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
Poggiolini, I., Gupta, V., Lawton, M., Lee, S., El-Turabi, A., Querejeta-Coma, A., Trenkwalder, C., Sixel-Döring, F., Foubert-Samier, A., Pavy-Le Traon, A., et al. (2022) · Brain · doi:10.1093/brain/awab431 · Cited by 191
da Silva, F. C., Iop, R. D. R., de Oliveira, L. C., Boll, A. M., de Alvarenga, J. G. S., Gutierres Filho, P. J. B., de Melo, L. M. A. B., Xavier, A. J., & da Silva, R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193113 · Cited by 189
Jurado-Coronel, J. C., Cabezas, R., Ávila Rodríguez, M. F., Echeverria, V., García-Segura, L. M., & Barreto, G. E. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.09.002 · Cited by 180
APOE genotype regulates pathology and disease progression in synucleinopathy
Davis, A. A., Inman, C. E., Wargel, Z. M., Dube, U., Freeberg, B. M., Galluppi, A., Haines, J. N., Dhavale, D. D., Miller, R., Choudhury, F. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3069 · Cited by 177
The importance of non-motor disturbances to quality of life in Parkinson's disease
Martinez-Martin, P. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.006 · Cited by 160
Sundaram, S., Hughes, R. L., Peterson, E., Müller-Oehring, E. M., Brontë-Stewart, H. M., Poston, K. L., Faerman, A., Bhowmick, C., & Schulte, T. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.016 · Cited by 152
Smith, K. M., & Caplan, D. N. (2018) · Brain and Language · doi:10.1016/j.bandl.2018.08.002 · Cited by 144
Quadri, M., Mandemakers, W., Grochowska, M. M., Masius, R., Geut, H., Fabrizio, E., Breedveld, G. J., Kuipers, D., Minneboo, M., Vergouw, L. J. M., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30179-0 · Cited by 143
Capturing Ambulatory Activity Decline in Parkinson's Disease
Cavanaugh, J. T., Ellis, T. D., Earhart, G. M., Ford, M. P., Foreman, K. B., & Dibble, L. E. (2012) · Journal of Neurologic Physical Therapy · doi:10.1097/npt.0b013e318254ba7a · Cited by 141
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018) · Movement Disorders · doi:10.1002/mds.27386 · Cited by 121
Allen, N. E., Sherrington, C., Suriyarachchi, G. D., Paul, S. S., Song, J., & Canning, C. G. (2012) · Parkinson's Disease · doi:10.1155/2012/854328 · Cited by 110
Metadata
- Authors
- Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2008-04-24
- Volume
- 23
- Issue
- 6
- Pages
- 837-844
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2016109926
- Cited by
- 2,246
- References
- 42
- FWCI
- 40.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Health and Medical Research Council of Australia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.